Drug pricing has emerged as a key topic to watch for pharmaceutical companies and investors in 2025. As President Donald Trump pushes for lower medicine prices for Americans, the sector is facing additional pricing pressure from a Biden-era law called the Inflation Reduction Act.The IRA, voted into law in 2022, allows the Centers for Medicare & Medicaid Services (CMS) to negotiate prices for a number of drugs each year for patients in Medicare, the federal health insurance program for seniors. It's now maki ...